Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

Figure 1

Consort scheduled scheme of the ARBI (Arimidex Bone Mass Index and Oral Bisphosphonates) clinical trial. The number of patients is included in data analysis. A, anastrozole; BMD, bone mineral density; DEXA, dual-energy x-ray absorptiometry; Dis., disease; F/up, follow-up; HP, hip; Invest., investigator; LS, lumbar spine; R, risedronate.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us